Kimberley S. Mak, MD, MPH
Assistant Professor, Radiation Oncology
Biography
Kimberley S. Mak, MD, MPH, is an Assistant Professor of Radiation Oncology at the Chobanian and Avedisian School of Medicine and its affiliate Boston Medical Center. She received her MPH from Harvard School of Public Health (2014), MD from Harvard Medical School (2010) and AB summa cum laude in Biochemical Sciences from Harvard College (2005). Dr. Mak completed an internship in Internal Medicine at Brigham and Women’s Hospital (2011), followed by residency in the Harvard Radiation Oncology Program (2015), training at Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Children’s Hospital of Boston, and Boston Medical Center. Dr. Mak has board certification in Radiation Oncology by the American Board of Radiology. She speaks English and Cantonese. Her specialties include thoracic, gastrointestinal, breast, and musculoskeletal malignancies. She leads the Cyberknife® radiosurgery program for thoracic and gastrointestinal malignancies.
Her research interests include patient-reported outcomes including quality of life; disparity outcomes research; translational research; intensity-modulated and image-guided radiotherapy; CyberKnife® stereotactic radiotherapy; and functional imaging in radiotherapy. She has training and experience in biostatistics, epidemiology, decision analysis, meta-analysis, clinical trial design, and molecular and cell biology laboratory work.
Other Positions
- Member, BU-BMC Cancer Center, Boston University
- Boston Medical Center
- VA Boston Healthcare System
Websites
Education
- Harvard Medical School, MD
- Harvard School of Public Health, MPH
- Harvard College, AB
Publications
- Published on 6/8/2023
Qureshi MM, Lin Y, Moeller AR, Yan SX, Dyer MA, Suzuki K, Everett P, Litle V, Truong MT, Mak KS. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer. J Surg Oncol. 2023 Oct; 128(5):781-789. PMID: 37288789.
Read at: PubMed - Published on 2/10/2023
Qureshi MM, Kam A, Suzuki K, Litle V, Tapan U, Balasubramaniyan R, Dyer MA, Truong MT, Mak KS. Association between hospital safety-net burden and receipt of trimodality therapy and survival for patients with esophageal cancer. Surgery. 2023 May; 173(5):1153-1161. PMID: 36774317.
Read at: PubMed - Published on 2/8/2023
Oladeru OT, Lam CM, Qureshi MM, Hirsch AE, Mak KS, Dyer MA, Truong MT. Inequalities in Cancer Stage at Diagnosis Among Incarcerated Individuals Undergoing Radiation Therapy at a Large Safety-Net Hospital. Int J Radiat Oncol Biol Phys. 2023 May 01; 116(1):194-198. PMID: 36758643.
Read at: PubMed - Published on 12/28/2022
Asokan S, Pavesi F, Bains A, Qureshi MM, Shetty S, Singh S, Mak KS, Litle VR, Suzuki K. Frailty Index is Associated with Treatment Decisions for Stage I Non-Small Cell Lung Cancer at a High-Burden Safety-Net Hospital. Clin Lung Cancer. 2023 Mar; 24(2):153-164. PMID: 36641324.
Read at: PubMed - Published on 12/25/2022
Siddiqi N, Pan G, Liu A, Lin Y, Jenkins K, Zhao J, Mak K, Tapan U, Suzuki K. Timeliness of Lung Cancer Care From the Point of Suspicious Image at an Urban Safety Net Hospital. Clin Lung Cancer. 2023 Mar; 24(2):e87-e93. PMID: 36642641.
Read at: PubMed - Published on 11/28/2022
Liu A, Siddiqi N, Tapan U, Mak KS, Steiling KA, Suzuki K. Black Race Remains Associated with Lower Eligibility for Screening Using 2021 US Preventive Services Task Force Recommendations Among Lung Cancer Patients at an Urban Safety Net Hospital. J Racial Ethn Health Disparities. 2022 Nov 28. PMID: 36441493.
Read at: PubMed - Published on 8/1/2022
Lee MH, Qureshi MM, Suzuki K, Everett P, Tapan U, Mak KS. Small cell lung cancer in young patients: trends in sociodemographic factors, diagnosis, treatment, and survival. J Thorac Dis. 2022 Aug; 14(8):2880-2893. PMID: 36071763.
Read at: PubMed - Published on 11/14/2021
Matthews BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, Oladeru OT, Truong MT, Hirsch AE, Mak KS, Dyer MA. Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer. Gynecol Oncol. 2022 01; 164(1):27-33. PMID: 34785030.
Read at: PubMed - Published on 9/24/2021
Huang D, Qureshi MM, Sarfaty S, Truong MT, Dyer MA, Mak KS, Hirsch AE. Longitudinal Outcomes of Medical Student Research Mentorship: a 15-Year Analysis of the Radiation Oncology Mentorship Initiative. J Cancer Educ. 2023 Feb; 38(1):153-160. PMID: 34558038.
Read at: PubMed - Published on 6/1/2021
Lin Y, Mak KS. Racial and socioeconomic disparities in the use of stereotactic body radiotherapy for treating non-small cell lung cancer: a narrative review. J Thorac Dis. 2021 Jun; 13(6):3764-3771. PMID: 34277068.
Read at: PubMed
View 31 more publications: View full profile at BUMC